CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia

Hematology Journal

Volumn 5, Issue 2, 2004, Pages 145-151

  Thornton, Patrick D ^a   Fernandez, Cristina ^a   Giustolisi, Giada M ^a   Morilla, Ricardo ^a   Atkinson, Shayne ^a   A'Hern, Roger P ^a   Matutes, Estella ^a   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CD38; CLL; Prognosis

Indexed keywords

CD38 ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TRISOMY 12;

ADP-RIBOSYL CYCLASE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD38; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1942506034     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200360     Document Type: Article

References (42)

1. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991; 78: 1901-1914.
2. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645.
3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
4. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
5. Binet JL, Catovsky D, Chandra P, Dighiero G, Montserrat E, Rai KR et al. Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Br J Haematol 1981; 48: 365-367.
6. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
7. French Cooperative Group on Chronic Lymphocytic Leukemia. Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients). Nouv Rev Fr Hematol 1988; 30: 363-367.
8. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929-936.
9. Montserrat E, Vinolas N, Reverter JC, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hématol 1988; 30: 359-367.
10. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567-575.
11. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45-57.
12. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC working party on leukaemia in adults. Br J Haematol 1989; 72: 141-149.
13. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996; 22: 439-447.
14. Di Giovanni S, Valentini G, Carducci P, Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 1989; 81: 181-185.
15. Melo JV, Catovsky D, Gregory WM, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 1987; 65: 23-29.
16. Criel A, Verhoef G, Vlietinck R, Mecucci C, Billiet J, Michaux L et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997; 97: 383-391.
17. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259-4264.
18. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1993; 1732-1737.
19. Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642-648.
20. Han T, Barcos M, Emrich L, Ozer H, Gajera R, Gomez GA et al. Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. J Clin Oncol 1984; 2: 562-570.
21. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Eng J Med 1990; 323: 720-724.
22. Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev 1994; 8: 88-97.
23. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
25. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
26. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-2457.
27. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, Sallstrom J et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001; 97: 1892-1894.
28. Matrai Z, Lin K, Dennis M, Sherrington P, Zuzel M, Pettitt AR et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 1902-1903.
29. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
30. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
31. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
32. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1269.
33. Orchard JA, Ibbotson RE, Davis Z, Stevenson FK, Hamblin TJ. Can CD38 Expression act as a surrogate marker for IG V Gene mutational status in CLL. Blood 2000; 96: 835a.
34. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA et al. Improvement of the chronic lymphocytic leukaemia scoring system with the monoclonal antibody SN8 (CD 79b). Am J Clin Pathol 1997; 108: 378-382.
35. Lengauer C, Speicher MR, Cremer T. FISH of Alu-PCR-amplified YAC clones and applications in tumor cytogenetics. Methods Molecular Biol 1994; 33: 85-94.
36. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187-220.
37. Pearson K. On a method of determining whether a sample of given size n supposed to have been drawn from a parent population having a known probability integral has probably been drawn at random. Biometrika 1933; 25: 370-410.
38. H genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997; 89: 4153-4160.
39. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
40. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F. Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil. Haematologica 2002; 87: 217-218.
41. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-2639.
42. Heintel D, Schwarzinger I, Chizzali-Bonfadin C, Thalhammer R, Schwarzmeier J, Fritzer-Szekeres M et al. Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 1315-1321.